TABLE 4.

BAL cell types by H&E staining and by flow cytometry at days 2 and 4 post-B1 or -CP52 challenge of FI-PIV3-immune mice treated with nIg F(ab)₂ or anti-SP F(ab)₂ antibodies

Type of analysis	Immunization + challenge + treatment	Cell typeb	Day 2 p.i.		Day 4 p.i.
			Range, % positive	Median % (P value)a	Range, % positive	Median % (P value)
H&E staining	FI-PIV3 + B1 + nIg	Macrophage	80–92	90 (>0.10)	81–97	88 (>0.10)
		PMN	0–6	4 (>0.10)	5–10	4 (>0.10)
		Eosinophil	0–3	1 (>0.10)	2–4	2 (>0.10)
		Lymphocyte	2–10	5 (<0.05)	5–10	6 (<0.01)
	FI-PIV3 + B1 + anti-SP	Macrophage	80–95	87	84–90	85
		PMN	0	0	0–8	4
		Eosinophil	2–5	3	0–4	1
		Lymphocyte	5–15	10	10–14	10
	FI-PIV3 + CP52 + nIg	Macrophage	90–98	96 (>0.10)	90–98	96 (<0.01)
		PMN	0	0 (>0.10)	0–3	2 (>0.10)
		Eosinophil	0	0 (>0.10)	0	0 (>0.10)
		Lymphocyte	2–8	4 (>0.10)	2–4	2 (<0.01)
	FI-PIV3 + CP52 + anti-SP	Macrophage	88–98	95	80–88	84
		PMN	0	0	4–12	6
		Eosinophil	0	0	1–5	2
		Lymphocyte	4–10	5	6–14	8
Flow cytometry	FI-PIV3 + B1 + nIg	CD4	20–28	26 (>0.10)	25–34	28 (>0.10)
		CD8	10–15	12 (>0.10)	15–21	18 (<0.01)
		B220	4–10	5 (>0.10)	9–14	10 (<0.01)
		DX5	2–8	5 (<0.01)	0–8	5 (<0.01)
		RB6-8C5	2–8	4 (>0.10)	2–10	5 (>0.10)
	FI-PIV3 + B1 + anti-SP	CD4	20–28	25	18–30	26
		CD8	8–20	15	10–15	12
		B220	3–6	4	2–10	5
		DX5	8–18	14	14–25	18
		RB6-8C5	2–11	7	5–10	6
	FI-PIV3 + CP52 + nIg	CD4	18–25	22 (>0.10)	20–28	25 (>0.10)
		CD8	8–15	10 (>0.10)	10–16	14 (>0.10)
		B220	4–10	8 (>0.10)	4–8	5 (>0.10)
		DX5	15–21	18 (>0.10)	20–26	24 (>0.10)
		RB6-8C5	10–16	15 (<0.01)	10–22	19 (>0.10)
	FI-PIV3 + CP52 + anti-SP	CD4	21–28	26	22–32	26
		CD8	6–18	8	8–20	15
		B220	4–10	5	4–9	5
		DX5	14–18	15	20–25	22
		RB6-8C5	4–12	8	12–20	15

^aFor comparison between nIg and anti-SP-treated mice given the same challenge virus. 

^bA lymphocyte gate was used to select 10,000 events for CD3⁺ and B220⁺ lymphocytes; 10,000 ungated events were used for analysis of DX5⁺, RB6-8C5⁺, and CD11b⁺ cells.